Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma.
about
Treatment options and outcomes for glioblastoma in the elderly patientThe accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expressionControversies in the adjuvant therapy of high-grade gliomas.MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Management of elderly patients with gliomasMolecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersRadiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysisMGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRToxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistanceOutcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy.Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?MGMT testing--the challenges for biomarker-based glioma treatment.Treating glioblastoma in the elderly.Relationship between cognitive function and prognosis in glioblastoma.Radiation therapy for older adults with glioblastoma: radical treatment, palliative treatment, or no treatment at all?Predictive biomarkers investigated in glioblastoma.Glioblastoma care in the elderly.Epigenetic alternations and cancer chemotherapy response.Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Endoscopy-verified occult subependymal dissemination of glioblastoma and brain metastasis undetected by MRI: prognostic significance.Elevated IQGAP1 and CDC42 levels correlate with tumor malignancy of human glioma.Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma?The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.MGMT promoter methylation as a potential prognostic marker for acute leukemia.Glioblastoma in elderly patients: solid conclusions built on shifting sand?Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.Primary brain tumors in the elderly population.
P2860
Q26991605-F42748F7-B0DB-43B1-B35F-93D6FEBB1A17Q28743982-C0EA8B16-1360-493D-93E1-091A1B66E724Q33394265-8B5D27B9-25F4-44D6-AC03-EF938C98F3BFQ34166477-8003E3CC-DC89-4B2B-A20A-04116CB55AC5Q34168829-43CB17BF-3FEF-4D1E-B748-C10114C10DF6Q34478948-1B48F013-7137-4735-8401-AFFA39C1FBFBQ34641001-FECF58D1-3120-447A-A53A-50AFC928866BQ34815207-A18463DA-DFBA-4A96-AFA3-DC40A084EDC4Q35004927-EAC89AE5-4C51-4BA9-A468-FC6D05783C3EQ35542866-BF74AC05-BB97-4AC0-9A52-FDAF2F17C19BQ35679476-45064AC0-B5E9-4E19-A4F2-CABC74B5C57EQ35850389-B6178FB4-4A88-48BF-9AF8-9544B8245FA0Q35943909-F44E41C5-7890-4F50-B569-8AF37A878A34Q36299167-A5FDCA44-20B5-49F4-9555-726E4B737169Q37109252-967E2DCA-A9EC-412C-80CA-6C4A3F0DC4FDQ37226536-D073DC55-C7A4-40DB-833C-728C7C2D4E8EQ37869402-CE344D15-098C-4D06-83A5-120F7AF83ABFQ38062793-65B3C141-DA33-443E-82C0-C130AC1C7C97Q38218848-84975BE9-EBDD-4E79-8623-56D829C8EAE5Q38233427-064864C0-FB16-444E-B624-49AD72298214Q38233450-F0639920-F4FD-455E-AF5D-048947D7CEC9Q38237311-C5EC052B-F6CA-4FF9-8D8F-A1B22BB15754Q38237337-9B614B6B-528D-48FC-BA4C-A07A9F1CD860Q38653138-B23C3E72-303B-477E-9F77-BA000B9EF473Q38680431-9ACA5662-B557-4E2B-931F-497968A719E4Q38773618-D5B3C87F-BF03-489F-BA34-051E2809073EQ39263561-3CE9B4BD-2FD7-415D-88FC-A1DF938CDC9CQ39266259-80C0528E-D4C8-4EF7-8E81-F19B1302E18FQ39275344-AA1984F6-9C9A-4E98-BB46-A9455BFD72FCQ41706326-8C859CA2-36EE-4D1F-BF9F-5AE135974780Q41781100-3B06DF97-C742-4D67-B34A-41B4B53D2E2EQ41895291-BA0413A1-B0A9-4BE1-B0B1-91E88B94E67AQ42364418-FDDC0AAE-75FF-48DA-BC36-506BA1F5C94DQ42704120-D032E1B9-4552-45C3-9BBD-D20AE4A35303Q45835773-AF5437D3-85FE-41AE-871D-6AD98C48D009Q47138733-2555E286-392A-4F8C-951C-8DA831F966CCQ47827482-187B3DB7-1648-476F-87DE-607C4801C34CQ48099567-27F6EC01-E19A-46C5-9913-AC95A8D6735CQ49640790-46FE2ACD-7834-4CB3-A4A6-73AC3FA9249DQ53083081-BB237C5C-8D3A-4508-B44B-6F354236399E
P2860
Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@en
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@nl
type
label
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@en
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@nl
prefLabel
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@en
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@nl
P2093
P2860
P1433
P1476
Mgmt methylation is a prognost ...... newly diagnosed glioblastoma.
@en
P2093
P2860
P304
P356
10.1212/WNL.0B013E3181BF9907
P407
P577
2009-11-01T00:00:00Z